NasdaqGM - Nasdaq Real Time Price • USD
Omeros Corporation (OMER)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 3 | 2 |
Avg. Estimate | -0.58 | -0.56 | -2.23 | -1.79 |
Low Estimate | -0.62 | -0.62 | -2.5 | -2.5 |
High Estimate | -0.53 | -0.43 | -1.69 | -1.09 |
Year Ago EPS | -0.54 | -0.59 | -1.88 | -2.23 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 3 | 2 |
Avg. Estimate | -- | -- | 16.67M | 6.5M |
Low Estimate | -- | -- | -- | -- |
High Estimate | -- | -- | 50M | 13M |
Year Ago Sales | -- | -- | -- | 16.67M |
Sales Growth (year/est) | -- | -- | -- | -61.00% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.56 | -0.57 | -0.61 | -0.55 |
EPS Actual | -0.54 | -0.59 | -0.6 | -0.15 |
Difference | 0.02 | -0.02 | 0.01 | 0.4 |
Surprise % | 3.60% | -3.50% | 1.60% | 72.70% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.58 | -0.56 | -2.23 | -1.79 |
7 Days Ago | -0.58 | -0.56 | -2.23 | -1.79 |
30 Days Ago | 0 | 0 | -1.78 | -1.54 |
60 Days Ago | 0 | 0 | -1.78 | -1.54 |
90 Days Ago | 0 | 0 | -1.78 | -1.54 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | OMER | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -7.40% | -- | -- | 2.60% |
Next Qtr. | 5.10% | -- | -- | 13.40% |
Current Year | -18.60% | -- | -- | 5.20% |
Next Year | 19.70% | -- | -- | 13.30% |
Next 5 Years (per annum) | 85.00% | -- | -- | 11.11% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Downgrade | Cantor Fitzgerald: Overweight to Neutral | 11/10/2023 |
Downgrade | UBS: Buy to Neutral | 12/8/2022 |
Downgrade | B of A Securities: Neutral to Underperform | 11/8/2022 |
Downgrade | B of A Securities: Buy to Neutral | 6/8/2022 |
Maintains | HC Wainwright & Co.: Buy | 10/19/2021 |
Downgrade | JP Morgan: Neutral to Underweight | 10/8/2021 |
Related Tickers
REPL Replimune Group, Inc.
6.15
-2.84%
LYRA Lyra Therapeutics, Inc.
5.17
-1.15%
MIRM Mirum Pharmaceuticals, Inc.
24.49
+1.96%
PHVS Pharvaris N.V.
22.77
+7.15%
BCRX BioCryst Pharmaceuticals, Inc.
4.1600
-1.19%
IMCR Immunocore Holdings plc
58.00
-0.80%
ZVRA Zevra Therapeutics, Inc.
4.5200
-0.88%
RCUS Arcus Biosciences, Inc.
14.73
-4.54%
RGNX REGENXBIO Inc.
16.06
+0.12%
FDMT 4D Molecular Therapeutics, Inc.
23.53
-2.97%